This is a news story, published by Yahoo, that relates primarily to Exviera news.
For more Exviera news, you can click here:
more Exviera newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
European Medicines Agency. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest AbbVie Deutschland GmbH news, dasabuvir news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
antiviral medicationsReuters
•81% Informative
European Medicines Agency says it has withdrawn marketing authorisation for Abbvie's hepatitis C drug Exviera .
The regulator said it withdrew the authorisation on Sept. 25 .
The drug was granted authorisation in the European Union in January 2015 for the treatment of chronic hepatitis C.
VR Score
90
Informative language
94
Neutral language
92
Article tone
formal
Language
English
Language complexity
70
Offensive language
likely offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links